🇺🇸 FDA
Patent

US 11242380

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 11242380 (Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use) held by Takeda Pharmaceutical Company Limited expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K39/39591, A61P